VACCINATION ANTI COVID-19 IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES

https://doi.org/10.56274/rcs.2022.1.1.6

Abstract

Introduction: the correct anti-Covid-19 immunization in immunocompromised patients is essential, but controversial regarding the immune response to vaccines and its interaction with the usual treatments of patients with primary immunodeficiencies (PID). Objective: to describe the anti-Covid -19 vaccination process in patients with primary immunodeficiencies registered in Granma. Method: a descriptive transversal research was carried out from may 2020 to july 2022, with 36 patients older than 2 years with primary immunodeficiencies in Granma. The data was collected from medical records and vaccination cards. For the absolute and relative frequencies, the statistical processor SPSS 25.0 was used. Results: the anti-Covid 19 vaccination was administered to 97.22% of the patients. All patients expressed interest and approval of the vaccination process. In addition, 100% of those over 11 years of age were immunized. Of the population expected to receive reinforcement, 68.75% received two reinforcements and 25% one; and 85.29% received a heterologous scheme. Conclusions: The most prevalent immunodeficiencies are humoral, led by IgA deficiency. All the immunodeficient showed acceptance of the vaccine and only one could not be vaccinated. The vaccines were safe and very little reactogenic in patients with PID and in the cases that events appeared they were mild and not related to vaccination. Immunodeficient children received a heterologous scheme and adults received both variants of the scheme. The level of reactivation was high among immunocompromised patients in Granma.